Design and methodology for the korean observational and escitalopram treatment studies of depression in acute coronary syndrome: K-DEPACS and EsDEPACS

Psychiatry Investigation

Volumn 11, Issue 1, 2014, Pages 89-94

  Kim, Jae Min ^a   Bae, Kyung Yeol ^a   Kang, Hee Ju ^a   Kim, Sung Wan ^a   Shin, Il Seon ^a   Hong, Young Joon ^a   Kim, Ju Han ^a   Shin, Hee Young ^a   Ahn, Young Keun ^a   Kim, Jong Keun ^a   Jeong, Myung Ho ^a   Yoon, Jin Sang ^a  

^a Chonnam National University Medical School   (South Korea)

Author keywords

Acute coronary syndrome; Clinical trial; Depression; Escitalopram; Observational study

Indexed keywords

CHOLESTEROL; ESCITALOPRAM; PLACEBO; TROPONIN I;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BECK DEPRESSION INVENTORY; BODY WEIGHT; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DSM-IV; ECHOCARDIOGRAPHY; FOLLOW UP; HAMILTON SCALE; HUMAN; INTERVENTION STUDY; KOREA; OBSERVATIONAL STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 84893327089     PISSN: 17383684     EISSN: 19763026     Source Type: Journal    
DOI: 10.4306/pi.2014.11.1.89     Document Type: Article

References (33)

1. Rudisch B, Nemeroff CB. Epidemiology of comorbid coronary artery disease and depression. Biol Psychiatry 2003;54:227-240.
2. Carney RM, Rich MW, Freedland KE, Saini J, teVelde A, Simeone C, et al. Major depressive disorder predicts cardiac events in patients with coronary artery disease. Psychosom Med 1988;50:627-633.
3. Strik JJ, Honig A, Lousberg R, Lousberg AH, Cheriex EC, Tuynman-Qua HG, et al. Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind, placebo-controlled trial. Psychosom Med 2000; 62:783-789.
4. Glassman AH, O'Connor CM, Califf RM, Swedberg K, Schwartz P, Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 2002;288:701-709.
5. Honig A, Kuyper AM, Schene AH, van Melle JP, de Jonge P, Tulner DM, et al. Treatment of post-myocardial infarction depressive disorder: a randomized, placebo-controlled trial with mirtazapine. Psychosom Med 2007;69:606-613.
6. Lesperance F, Frasure-Smith N, Koszycki D, Laliberte MA, van Zyl LT, Baker B, et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial. JAMA 2007;297:367-379.
7. Dowlati Y, Herrmann N, Swardfager WL, Reim EK, Lanctot KL. Efficacy and tolerability of antidepressants for treatment of depression in coronary artery disease: a meta-analysis. Can J Psychiatry 2010;55:91-99.
8. Jiang W, Krishnan RR, O'Connor CM. Depression and heart disease: evidence of a link, and its therapeutic implications. CNS Drugs 2002; 16:111-127.
9. Bush DE, Ziegelstein RC, Tayback M, Richter D, Stevens S, Zahalsky H, et al. Even minimal symptoms of depression increase mortality risk after acute myocardial infarction. Am J Cardiol 2001;88:337-341.
10. Rallidis LS, Varounis C, Sourides V, Charalampopoulos A, Kotakos C, Liakos G, et al. Mild depression versus C-reactive protein as a predictor of cardiovascular death: a three year follow-up of patients with stable coronary artery disease. Curr Med Res Opin 2011;27:1407-1413.
11. Flock A, Zobel A, Bauriedel G, Tuleta I, Hammerstingl C, Hofels S, et al. Antiplatelet effects of antidepressant treatment: a randomized comparison between escitalopram and nortriptyline. Thromb Res 2010; 126:e83-e87.
12. Hanash JA, Hansen BH, Hansen JF, Nielsen OW, Rasmussen A, Birket-Smith M. Cardiovascular safety of one-year escitalopram therapy in clinically nondepressed patients with acute coronary syndrome: results from the DEpression in patients with Coronary ARtery Disease (DECARD) trial. J Cardiovasc Pharmacol 2012;60:397-405.
13. Beck AT, Ware CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-571.
14. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The mini-international neuropsychiatric interview (M.I.N. I): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59(Suppl 20): 22-33.
15. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
16. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389.
17. Guy W. ECDEU Assessment Manual for Psychopharmacology. Revised. Rockville: National Institute of Mental Health; 1976.
18. Davidson KW, Kupfer DJ, Bigger JT, Califf RM, Carney RM, Coyne JC, et al. Assessment and treatment of depression in patients with cardiovascular disease: National Heart, Lung, and Blood Institute Working Group Report. Psychosom Med 2006;68:645-650.
19. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition. Washington, DC: American Psychiatric Association; 1994.
20. Eipping-Jordan J, Ustun TB, Assessment, Classification and epidemiology Group. The WHODAS II: levelling the playing field for all disorders. WHO Mental Health Bull 2000;6:5-6.
21. Development of the World Health Organization WHOQOL-BREF quality of life assessment. The WHOQOL Group. Psychol Med 1998; 28:551-558.
22. Fava GA, Ruini C, Belaise C. The concept of recovery in major depression. Psychol Med 2007;37:307-317.
23. John OP, Srivastata S. The Big Five Trait taxonomy: History, Measurement, and Theoretical Perspectives. In: Pervin LA, John OP, Editors. Handbook of Personality, 2nd Edition. New York: The Guilford Press; 1999, p.102-138.
24. Ahn YM, Lee KY, Yi JS, Kang MH, Kim DH, Kim JL, et al. A validation study of the Korean-version of the Montgomery-Asberg Depression Rating Scale. J Korean Neuropsychiatr Assoc 2005;44:466-476.
25. Chung YC, Rhee MK, Lee YH, Park SH, Shon CH, Lee BK, et al. Standardization study of Beck Depression Inventory 1-Korean version (KBDI): reliability and factor analysis. Korean J Psychopathol 1995;4:77-95.
26. Kim JM, Stewart R, Glozier N, Prince M, Kim SW, Yang SJ, et al. Physical health, depression and cognitive function as correlates of disability in an older Korean population. Int J Geriatr Psychiatry 2005;20:160-167.
27. Lee JY, Cho MJ, Kwon JS. Global Assessment of Functioning Scale and Social and Occupational Functioning Scale. Korean J Psychopharmacol 2006;17:122-127.
28. Yi JS, Bae SO, Ahn YM, Park DB, Noh KS, Shin HK, et al. Validity and reliability of the Korean version of the Hamilton Depression Rating Scale (K-HDRS). J Korean Neuropsychiatr Assoc 2005;44:456-465.
29. Yoo SW, Kim YS, Noh JS, Oh KS, Kim CH, Namkoong K, et al. Validity of Korean version of the Mini-International Neuropsychiatric Interview. Anxiety Mood 2006;2:50-55.
30. Kim SY, Kim JM, Yoo JA, Bae KY, Kim SW, Yang SJ, et al. Standarization and validation of Big Five Inventory-Korean Version (BFI-K) in elders. Korean J Biol Psychiatry 2010;17:15-25.
31. Yoon JS, Yoon BH, Choi TS, Kim YB, Lee HY. A double-blind comparison of paroxetine and amitriptyline in the treatment of depression accompanied by alcoholism: behavioral side effects during the first 2 weeks of treatment. J Korean Soc Biol Psychiatry 1996;3:277-287.
32. Kim JM, Kim SW, Stewart R, Kim SY, Yoon JS, Jung SW, et al. Predictors of 12-week remission in a nationwide cohort of people with depressive disorders: the CRESCEND study. Hum Psychopharmacol 2011;26:41-50.
33. Marks DM, Thanasellan J, Pae CU. Innovations in clinical research design and conduct in psychiatry: shifting to pragmatic approaches. Psychiatry Investig 2009;6:1-6.